CAS: 1113-59-3; 3-Bromopyruvic Acid

上下游产品

CAS号127-17-3 丙酮酸 | CAS号113-24-6 丙酮酸钠 | CAS号14214-10-9 3-二氮杂-2-氧代丙酸乙酯 | CAS号123-54-6 乙酰丙酮 | CAS号7732-18-5 水 | CAS号7726-95-6 溴素 | CAS号1113-60-6 羟基丙酮酸 | CAS号1113102-07-0 5-methoxycarbon... | CAS号526-78-3 2,3-二溴丁二酸 | CAS号110-15-6 琥珀酸； 丁二酸 | CAS号79-08-3 溴乙酸 | CAS号6305-43-7 1,4-二溴-2,3-丁二酮 | CAS号3369-79-7 Β-羟基丙酮酸锂 水合物 | CAS号911466-96-1 2-(乙氧基羰基)噻唑-4-羧酸 | CAS号127-17-3 丙酮酸 | CAS号62235-61-4 3-(溴甲基)喹喔啉-2(1H)-酮

丙酮酸置于溴体系中,化学反应生成3-溴丙酮酸
参考文献:Practical Synthesis Of 2-(2-Isopropylaminothiazol-4-yl)-7-Methoxy-1H-Quinolin-4-One: Key Intermediate For The Synthesis Of Potent Hcv Ns3 Protease Inhibitor Biln 2061
标题:Practical Synthesis Of 2-(2-Isopropylaminothiazol-4-yl)-7-Methoxy-1H-Quinolin-4-One: Key Intermediate For The Synthesis Of Potent Hcv Ns3 Protease Inhibitor Biln 2061
摘要:在此,我们描述了一种高效,安全且实用的 7-甲氧基-2-(2-氨基-4-噻唑基)喹啉合成工艺的开发.我们的新工艺允许采用更加收敛的方法,并消除了潜在危险试剂的使用,例如先前发现方法中使用的重氮甲烷.
Doi:10.1055/s-2006-942472

专利信息

专利号:US-2025049961-A1
优先权日:2021-12-23
标题 :Scalable and high-purity cell-free synthesis of closed-ended dna vectors
发明人：MONDS RUSSELL; CIPI JORIS; BLACKSTOCK DANIEL JASON; DURANT JOHN CHESTER
权利人:GENERATION BIO CO
摘要:This disclosure provides methods for scalable and high-purity cell-free synthesis of DNA vectors, particularly closed-ended DNA vectors (e.g., ceDNA vectors) having linear and continuous structure for delivery and expression of a transgene. The cell-free synthesis includes digesting a double-stranded DNA construct with at least one restriction endonuclease that is capable of cleaving the construct at cleavage sites, which are distinct from the recognition sites, to release an insert having unique overhangs that regulate the high specificity of the subsequent ligation reaction. The insert is then ligated with inverted terminal repeat (ITR) oligonucleotides to form the closed-ended DNA vector. Corresponding DNA vectors prepared by these methods and related products as well other base and intermediate vectors and constructs associated with the methods are also provided in this disclosure.

专利号:US-11311505-B2
优先权日:2017-02-24
标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.

专利号:US-7781488-B2
优先权日:2002-06-10
标 题:Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
发明人：BOTTI PAOLO; VILLAIN MATTEO; MANGANIELLO SONIA; GAERTNER HUBERT
权利人:AMYLIN PHARMACEUTICALS INC
摘要:The present invention provides a method and compositions for synthesizing an oligopeptide or polypeptide by convergent assembly of a plurality of pairs of oligopeptides in chemical ligation reactions. An important aspect of the present invention is an oligopeptide having a C-terminal disulfide-protected carboxythioester group that can be deprotected to spontaneously generate a free C-terminal thioester moiety. This allows a single precursor to participate in a succession of chemical ligation reactions, thereby making the convergent synthesis approach possible. The present invention is useful in methods for chemical synthesis of oligopeptides, polypeptides and proteins, and improves the efficiency of native chemical ligation reactions, particularly where four or more peptide fragments are used to assemble an oligopeptide, polypeptide or protein product.

专利号:US-10813893-B2
优先权日:2017-02-24
标 题:Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:The present invention has shown that not all salts of pyruvic acid enhance lung functions or enhance the synthesis of lung surfactants and that certain salts of pyruvic acid with the correct concentrations of calcium, phosphate and magnesium, are synergistic in their ability to enhance the synthesis of lung surfactants that will enhance lung alveoli functions, while decreasing coughing and lung tightness, and increasing oxygen saturation values to prevent hypoxemia. This patent demonstrates that the sodium pyruvate formula with calcium, phosphate and magnesium was superior over standard sodium pyruvate formula in saline alone in the removal of mucus, reduction of lung or sinus infections, and in reducing drug side effects and congestion. The use of this formula clearly demonstrated that it can be used to produce better efficacy in patients with hypoxemia, with lung and sinus diseases including, asthma, COPD, cystic fibrosis, interstitial lung disease, allergic rhinitis, sinusitis, Alzheimer's, disease, Parkinson's disease, brain trauma, nicotine addiction, sleep apnea, autism, migraine headaches, sleep disorders, lung and sinus infections, cancer therapy with cancer drugs, nicotine addiction, and medications that cause a decrease in lung surfactants.

专利号:US-11628186-B2
优先权日:2017-02-24
标题 :Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.

专利号:US-6608196-B2
优先权日:2001-05-03
标题 :Process for solid supported synthesis of pyruvate-derived compounds
发明人：WANG BING; JANAGANI SATYANARAYANA; CALLAWAY WYETH B; SESSLER JONATHAN L
权利人:GALILEO PHARMACEUTICALS INC
摘要:Provided are processes for synthesizing structurally diverse pyruvate-derived compounds using a parallel approach on a solid phase support. Examples of such a solid phase support include resins which have also been used in solid phase peptide synthesis.